^
No biomarker
Rectal Cancer
FOLFIRI
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
irinotecan
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
MSI-H/dMMR
Rectal Cancer
nivolumab
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
FOLFOXIRI
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
FOLFOX
Sensitive: A2 - Guideline
MSI-H/dMMR
Rectal Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
CAPOX
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
5-fluorouracil
Sensitive: A2 - Guideline
MSI-H/dMMR
Rectal Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
trifluridine/tipiracil
Sensitive: A2 - Guideline
HER-2 amplification
Rectal Cancer
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
HER-2 amplification
Rectal Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
HER-2 amplification
Rectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
NTRK3 fusion
Rectal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Rectal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Rectal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Rectal Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Rectal Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Rectal Cancer
entrectinib
Sensitive: A2 - Guideline
BRAF V600
Rectal Cancer
cetuximab + encorafenib
Sensitive: A2 - Guideline
BRAF V600
Rectal Cancer
panitumumab + encorafenib
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
ramucirumab
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
ziv-aflibercept IV
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
5-fluorouracil + leucovorin calcium
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
mFOLFOX6
Sensitive: A2 - Guideline
No biomarker
Rectal Cancer
regorafenib
Sensitive: A2 - Guideline
UGT1A1*1*1
Rectal Cancer
capecitabine + irinotecan
Sensitive: B - Late Trials
No biomarker
Rectal Cancer
FOLFIRINOX + mFOLFOX6
Sensitive: B - Late Trials
MSI-H/dMMR
Rectal Cancer
sintilimab
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Rectal Cancer
nivolumab
Sensitive: C3 – Early Trials
TMB-H
Rectal Cancer
nivolumab
Sensitive: C3 – Early Trials
TACC3 expression
Rectal Cancer
5-fluorouracil
Resistant: C3 – Early Trials
TACC3 expression
Rectal Cancer
FOLFOX
Resistant: C3 – Early Trials
TACC3 expression
Rectal Cancer
CAPOX
Resistant: C3 – Early Trials
TACC3 expression
Rectal Cancer
capecitabine
Resistant: C3 – Early Trials
KRAS mutation + ATM mutation
Rectal Cancer
bevacizumab
Sensitive: C4 – Case Studies
MSI-H/dMMR
Rectal Cancer
ipilimumab
Sensitive: C4 – Case Studies
PAI1 expression
Rectal Cancer
AZD1208
Sensitive: D – Preclinical